Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
Description
Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that were funded during the boom and ended up driving the generalists away, said MPM Bioimpact's Chris Bardon on The BioCentury Show. Bardon said the market hasn’t yet found the footing that will see an opening of the IPO window and a swing of positive sentiment. But although markets aren’t yet out of the woods, she said M&A will remain robust for years, fueled by obesity drug revenues.
View full story: https://www.biocentury.com/article/654649
#biotech #biopharma #pharma #lifescience #financing #investing
00:00 - Introduction
01:30 - Market Sentiment
06:19 - IPO Window
12:04 - M&A Outlook
19:51 - The Obesity Landscape
United States
